Therapeutics News and Research

RSS

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

23 Jun 2014

Dimension Therapeutics closes $30M financing to advance novel gene therapy programs

Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced the closing of a $30 million financing.

23 Jun 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

Researchers explore genetic and cellular mechanisms of retinal development

The circuitry of the central nervous system is immensely complex and, as a result, sometimes confounding. When scientists conduct research to unravel the inner workings at a cellular level, they are sometimes surprised by what they find.

20 Jun 2014

FAK inhibitors prevent ovarian cancer progression

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors to a protein called focal adhesion kinase (FAK) selectively prevent the growth of ovarian cancer cells as tumor spheroids.

20 Jun 2014

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

According the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood.

20 Jun 2014

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.

19 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer Inc. and Cellectis today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

18 Jun 2014

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

The last 20 years have been defined by progress and innovation in the multiple sclerosis (MS) field, with now 10 approved treatment options available for people living with relapsing MS, the most common form of the disease.

17 Jun 2014

Gluten-free diet can improve 'brain fog' in individuals with celiac disease

Individuals with celiac disease often experience 'brain fog' in addition to intestinal problems, but a new study shows that adhering to a gluten-free diet can lead to improvements in cognition that correlate with the extent of intestinal healing.

17 Jun 2014

Autistic-like behaviors linked with disruption of Adenomatous Polyposis Coli gene

Autistic-like behaviors and decreased cognitive ability may be associated with disruption of the function of the Adenomatous Polyposis Coli (APC) gene.

17 Jun 2014

New technique to uncover building blocks of kidney regeneration

Doctors and scientists have for years been astonished to observe patients with kidney disease experiencing renal regeneration. The kidney, unlike its neighbor the liver, was universally understood to be a static organ once it had fully developed.

17 Jun 2014

Affordable Care Act to have significant impact on patients with diabetes

The Affordable Care Act (ACA, also known as Obamacare) is dramatically changing health care delivery in the U.S. Specific parts of the new law, which will be phased in through 2020, will have a significant impact on patients with diabetes and prediabetes, as explored in a comprehensive Review article published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

17 Jun 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

We start with birth and we collect the cells after C-section. The reason for that is we have to have the mother sign a consent letter that she is donating the placenta and, on top of that, we have to have a blood sample from the mother to test for any viral contamination.

16 Jun 2014

Researchers identify tremendous genetic diversity

In the most comprehensive genetic study of the Mexican population to date, researchers from UC San Francisco and Stanford University, along with Mexico's National Institute of Genomic Medicine (INMEGEN), have identified tremendous genetic diversity, reflecting thousands of years of separation among local populations and shedding light on a range of confounding aspects of Latino health.

13 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

Therapeutics News and Research

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics closes $30M financing to advance novel gene therapy programs

Celsion acquires all assets of EGEN

SCLC tumours replicated in mice from patients' CTCs

Researchers explore genetic and cellular mechanisms of retinal development

FAK inhibitors prevent ovarian cancer progression

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Gluten-free diet can improve 'brain fog' in individuals with celiac disease

Autistic-like behaviors linked with disruption of Adenomatous Polyposis Coli gene

New technique to uncover building blocks of kidney regeneration

Affordable Care Act to have significant impact on patients with diabetes

Arrowhead Research joins with broad-market Russell 3000 Index

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Researchers identify tremendous genetic diversity

New research collaboration aims to develop better therapies for autoimmune diseases

Healthcare Corporate Access Day to be held on June 24, 2014

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News